hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06290739 id: JHuang886 briefTitle: A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma overallStatus: RECRUITING date: 2024-02-07 date: 2024-03-07 date: 2024-03-27 date: 2024-03-04 date: 2024-03-04 name: West China Hospital class: OTHER briefSummary: The object of this study is to develop a model for prediction of lymph node metastasis among intrahepatic cholangiocarcinoma (ICC) patients. Intrahepatic cholangiocarcinoma is the second most common kind of primary liver cancer, accounting for approximately 10%-15%. There is a lack of agreement regarding the necessity of performing lymph node dissection (LND) in patients with ICC. Currently, the percentage of LND is below 50%, and the rate of sufficient LND (≥6) has plummeted to less than 20%. Consequently, a large proportion of patients are unable to acquire LN status, which hinders the following systematic treatment strategies after surgery:. Therefore, our objective is to construct a LN metastasis model utilizing machine learning techniques, including patients' clinical data and pathology information, with the goal of offering a reference for patients who have not undergone LND or have had inadequate LND. conditions: Intrahepatic Cholangiocarcinoma conditions: Machine Learning studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 300 type: ESTIMATED name: lymph nodes dissection measure: Overall survival measure: Disease free survival sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University status: RECRUITING city: Chengdu state: Sichuan zip: 610041 country: China name: fengmin Luo, Doctor role: CONTACT phone: +86 028-85582944 email: hxyyhfb@163.com lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06290726 id: 202001927B0 briefTitle: Long-term Outcomes of Living Donor Liver Transplantations With Anti-HBc (+) Grafts in Pediatric Patients overallStatus: COMPLETED date: 2002-02 date: 2016-02 date: 2024-01 date: 2024-03-04 date: 2024-03-05 name: Chang Gung Memorial Hospital class: OTHER briefSummary: The goal of this observational study is to compare in anti-HBc (+) grafts/ anti-HBc (-) grafts. The main question it aims to answer is the long-term efficacy of active vaccination and graft/patient outcomes of anti-HBc (+) grafts have yet to be comprehensively investigated. Researchers will compare anti-HBc (+) grafts/ anti-HBc (-) to see if it would affect the long-term survival. conditions: Living Donor Liver Transplantations With Anti-HBc (+) Grafts studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 204 type: ACTUAL measure: Long-term survival in pediatric recipients of living donor liver transplantations with anti-HBc (+) grafts sex: ALL minimumAge: 4 Months maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06290700 id: MCBU_2880 briefTitle: Effect of Neonatal Care Education for Primiparous Pregnant Women on Postpartum Maternal Function and Quality of Life overallStatus: COMPLETED date: 2022-11-01 date: 2024-02-01 date: 2024-02-01 date: 2024-03-04 date: 2024-03-04 name: Celal Bayar University class: OTHER briefSummary: This study aimed to evaluate the effect of neonatal care education for primiparous pregnant women on postpartum maternal function and quality of life. conditions: Life Quality conditions: Functional Status studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 126 type: ACTUAL name: Neonatal Care education measure: severity of maternal function by Barkin Index of Maternal Functioning measure: Maternal Postpartum Quality of Life Instrument sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Yonca ÇIÇEK OKUYAN city: Manisa country: Turkey lat: 38.61202 lon: 27.42647 hasResults: False
nctId: NCT06290687 id: CASE5824 briefTitle: Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-01-29 date: 2027-01-29 date: 2024-03-04 date: 2024-03-06 name: Case Comprehensive Cancer Center class: OTHER briefSummary: The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and oncologic efficacy of the intervention, and to examine patient-reported quality of life outcomes in participants. Participants will receive the standard pre-surgery treatment for approximately 4 to 6 weeks. After the pre-surgery treatment is completed, participants will undergo a partial cystectomy with extended pelvic lymph node dissection. After surgery, participants will receive adjuvant systemic therapy. conditions: Malignant Neoplasm of Bladder conditions: Muscle Invasive Bladder Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a single-center, prospective, phase II trial. primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Neoadjuvant Chemotherapy name: Partial cystectomy with Extended pelvic lymph node dissection name: Adjuvant systemic therapy measure: Recurrence-Free Survival (RFS) measure: Presence of Post-operative Complications measure: Median Bladder RFS measure: Median Muscle-Invasive Bladder RFS measure: Median Bladder-Intact Survival measure: Median Cancer-Specific Survival measure: Changes in Genitourinary-specific HRQoL sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Glickman Urological and Kidney Institute, Cleveland Clinic, Case Comprehensive Cancer Center city: Cleveland state: Ohio zip: 44195 country: United States name: Nima Almassi, MD role: CONTACT phone: 216-444-1825 email: almassn2@ccf.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06290674 id: P.T.REC/012/004043 briefTitle: Extracorporeal Shockwave on Abdominal Adiposity and Lipid Profile overallStatus: COMPLETED date: 2022-09-11 date: 2024-01-01 date: 2024-02-01 date: 2024-03-04 date: 2024-03-07 name: Adly A Adam class: OTHER briefSummary: Almost postmenopausal women store significant extra visceral adipose tissue with unexplained mechanism, yet. Postmenopausal obese women with excess abdominal obesity have raised metabolic risk of numerous cardiovascular diseases, which negatively influence health policy concern. Therefore, actual need to recommend non-invasive approach that cover this lack of quantitative knowledge in clinical management of obese postmenopausal women. conditions: Obesity, Abdominal studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Clinical randomized controlled study primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double masking (Investigator and Participant) whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ACTUAL name: Extracorporeal Shockwave therapy name: Balanced low-calorie diet measure: Waist/ hip ratio measure: Skin fold caliper measure: Lipid profile sex: FEMALE minimumAge: 45 Years maximumAge: 60 Years stdAges: ADULT facility: Helwan General Hospital city: Cairo state: Helwan, Cairo Governate zip: 02 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06290661 id: UHCT-IEC-SOP-016-03-01 briefTitle: Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Postherpetic Neuralgia. overallStatus: RECRUITING date: 2023-02-09 date: 2024-12-31 date: 2025-06-30 date: 2024-03-04 date: 2024-03-04 name: Wuhan Union Hospital, China class: OTHER name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine name: The Second People's Hospital of GuangDong Province name: Xiamen Hospital of Traditional Chinese Medicine briefSummary: The goal of this clinical trial is to evaluate safety and efficacy of percutaneous peripheral nerve stimulation in patients with postherpetic neuralgia. The main questions it aims to answer are:
2. The safety of percutaneous peripheral nerve stimulation in patients with postherpetic neuralgia Participants are going to undergo procedure that implant peripheral nerve stimulation electrode produced by Jiangsu CED Medtech Co., Ltd. Then the subjects, whose VAS scores decrease more 30% than baseline level, are classified into two groups randomly. One of the group receiving active stimulation called trial group and another receiving placebo stimulation called control group. All subjects are required to make their own subjects' pain diary to record VSA score before and after implantation until at the end of follow-up. Also, participants are asked to report use of analgesic medications, number of awakenings and adverse events.
Researchers will compare pain scores between the two groups to see if peripheral nerve stimulation is effective to patients with postherpetic neuralgia. conditions: Neuropathic Pain conditions: Postherpetic Neuralgia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Active electrostimulation name: Placebo electrostimulation measure: Difference in mean pain visual analogue scale VAS scores between trial and control groups in the randomised withdrawal period measure: Visual simulation assessment scale collects pain scores after peripheral electrode placement measure: Proportion of subjects whose pain relief more than 30% measure: Proportion of subjects of ideal pain state measure: Sleep-related assessment after electrostimulation measure: Change of life quality after electrostimulation measure: Analgesic medications measure: Stability of external assistant devices measure: Questionnaire survey equipment satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Union Hospital, Tongji medical college, Huazhong University of Science and Technology status: RECRUITING city: Wuhan state: Hubei zip: 430022 country: China name: Dong Yang, PHD role: CONTACT phone: 13871230491 phoneExt: 86 email: dongyang118@sina.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06290648 id: 22-0868 id: 5R34MH130555 type: NIH link: https://reporter.nih.gov/quickSearch/5R34MH130555 briefTitle: Forging New Paths: Building Interventions to Treat Criminogenic Needs in Community Based Mental Health Settings acronym: FNP overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-12 date: 2025-12 date: 2024-03-04 date: 2024-03-04 name: University of North Carolina, Chapel Hill class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: The goal of this clinical trial is to conduct a preliminary test of the effectiveness of Forging New Paths for people with mental illness with criminal legal system contact. The main question\[s\] it aims to answer are:
Participants will complete a screening interviews to see if they are eligible. Participants who are eligible will be randomly assigned to participate in one of two study conditions: Forging New Paths and usual care or usual care alone. All participants who are assigned to a study condition will participate in up to three additional research interviews. Researchers will also collect information about study outcomes using administrative records. conditions: Mental Illness studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 72 type: ESTIMATED name: Forging New Paths measure: Change in Levels of Aggression Score from Baseline to Month 3 measure: Change in Levels of Aggression Score From Baseline to Month 6 measure: Community Tenure measure: Change in Overall Criminal Attitudes Score measure: Change in Overall Impulsivity Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of North Carolina at Chapel Hill city: Chapel Hill state: North Carolina zip: 27599 country: United States name: Amy Wilson, PhD role: CONTACT lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06290622 id: IRB300012414 (UAB23136) briefTitle: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2026-06-30 date: 2028-01-31 date: 2024-03-04 date: 2024-04-24 name: University of Alabama at Birmingham class: OTHER briefSummary: This study is investigating the optimal dose and the advantage in combining investigational immunotherapy drugs known as Retifanlimab, INCAGN02385 and INCAGN02390 to improve the responses to CAR T-cell therapy. Additionally, the study will investigate that triple checkpoint blockade of PD-1, TIM-3 and LAG-3 molecules will overcome CAR T-cell therapy resistance in patients with suboptimal responses. conditions: Diffuse Large B Cell Lymphoma conditions: Lymphoma, B-Cell conditions: Lymphoma, Follicular studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: Retifanlimab, INCAGN02385, INCAGN02390 measure: Identify the optimal biological dose (OBD) for Retifanlimab in combination with INCAGN02385 and INCAGN02390 in relapsed/refractory DLBCL. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama at Birmingham city: Birmingham state: Alabama zip: 35294 country: United States name: Margaret Thomas role: CONTACT email: margaretannthomas@uabmc.edu name: Mayur Narkhede, MD role: PRINCIPAL_INVESTIGATOR name: Amitkumar Mehta, MD role: SUB_INVESTIGATOR name: Lauren Shea, MD role: SUB_INVESTIGATOR name: Gaurav Goyal, MD role: SUB_INVESTIGATOR lat: 33.52066 lon: -86.80249 hasResults: False
nctId: NCT06290609 id: 72799 briefTitle: Vibrotactile Coordinated Reset for Spasticity After Spinal Cord Injury overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-06-15 date: 2024-06-15 date: 2024-03-04 date: 2024-03-04 name: Stanford University class: OTHER briefSummary: The purpose of our study is to evaluate vibrotactile Coordinated Reset (vCR) and its effects on spasticity symptoms in incomplete spinal cord injured patients. vCR will be administered with a device called the Stanford CR Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as oral baclofen and or deep brain stimulation. Patients will be followed for three months and will be asked to come to the lab for clinical testing 4 times during this period. A total of 30 patients will be included in the study. conditions: Spasticity, Muscle conditions: Spinal Cord Injuries studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A single group of participants who will receive active treatment with the experimental stimulation device will be studied. primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Vibrotactile Coordinated Reset measure: Change from baseline in spasticity with the Modified Ashworth Scale (MAS) at 2 hours, 1 week, 4 weeks, and 12 weeks. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stanford University city: Stanford state: California zip: 94305 country: United States name: Peter Tass, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 37.42411 lon: -122.16608 hasResults: False
nctId: NCT06290596 id: MSR/AZAST/AIP029/21/222/8/2023 briefTitle: Vasopressin Versus Tranexamic Acid for Control of Blood Loss Related to Abdominal Hysterectomy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2024-10-01 date: 2024-03-04 date: 2024-03-06 name: Al-Azhar University class: OTHER briefSummary: To find the best option to reduce blood loss related to abdominal hysterectomy (AH), the present randomized double-blinded study sought to compare the effects of locally administered vasopressin (VP) and tranexamic acid (TXA) on blood loss in women submitted to AH for benign lesions. conditions: Uterine Surgery studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 387 type: ESTIMATED name: Vasopressin name: Tranexamic acid name: Saline measure: blood loss sex: FEMALE minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06290583 id: Prilocaine in cesarean section briefTitle: Comparing the Effect of Spinal Bupivacaine Versus Spinal Prilocaine on Maternal Blood Pressure in Cesarean Section overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-11 date: 2024-12 date: 2024-03-04 date: 2024-03-05 name: South Valley University class: OTHER briefSummary: one of the most common complications associated with spinal anesthesia is hypotension, which can have adverse effects on both the mother and the fetus. The present study compare prilocaine versus bupivacaine in spinal anesthesia on hypotension and there effect on maternal outcomes. conditions: Spinal Anesthetics Causing Adverse Effects in Therapeutic Use studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Bupivacaine name: Prilocaine measure: Maternal arterial blood pressure measure: Evaluation of duration of motor block measure: Total dose of ephedrine sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06290570 id: 23-007685 briefTitle: A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's Heart overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-09 date: 2025-09 date: 2024-03-04 date: 2024-04-03 name: Mayo Clinic class: OTHER briefSummary: The purpose of this study is to evaluate the AI-ECG algorithm for HCM in detecting HCM and in differentiating it from athlete's heart using not only the standard 12-lead ECG, but also ECGs obtained with the Apple Watch and Alivecor KardiaMobile devices. conditions: Hypertrophic Cardiomyopathy conditions: Athlete Heart studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: 12-Lead ECG name: Apple Smart Watch Single Lead ECG name: AliveCor KardiaMobile 6-Lead ECG measure: Distribution of AI-ECG probabilities in HCM measure: Comparative diagnostic performance between tracings obtained from different devices measure: Distribution of AI-ECG probabilities in Athlete's Heart measure: Correlation with false negative AI ECG result sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States name: Heart Rhythm Services Research Team role: CONTACT phone: 507-255-0774 name: Konstantinos Siontis, MD role: CONTACT phone: (507) 255-1051 email: Siontis.Konstantinos@mayo.edu name: Konstantinos Siontis, MD role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06290557 id: 2023-507737-17-00 briefTitle: First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133 acronym: HY-133 overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-07-01 date: 2026-07-01 date: 2024-03-04 date: 2024-03-05 name: University Hospital Tuebingen class: OTHER briefSummary: In this clinical trial we will test a new approach for decolonization of S. aureus.
As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five times in one day. To avoid possible bias the subjects will be randomized 3:2 verum vs placebo, moreover the subject as well as the investigator will be blinded to the group assigned. conditions: Staphylococcus Aureus studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 52 type: ESTIMATED name: HY_133 name: Placebo measure: ADRs/AEs/SAEs occurring from the time of application until the final study visit (Day15) for each subject sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06290544 id: CCM 1552 briefTitle: Cardiovascular Risk Assessment in a Cohort of Italian Patients With Type 1 Diabetes Mellitus (CARDT1) acronym: CARDT1 overallStatus: RECRUITING date: 2021-11-29 date: 2026-07 date: 2026-07 date: 2024-03-04 date: 2024-03-04 name: Centro Cardiologico Monzino class: OTHER briefSummary: This is a multicenter prospective collection of data with diagnostic procedures different from standard clinical care in a specific cohort of patients, aimed to evaluate cardiovascular risk stratification with the European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) guidelines and "The Steno Type 1 Risk Engine" algorithm. The correlation between CVD risk, atherosclerosis, and microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy) will then be evaluated, and the impact of glycemic variability and other glucose metrics on vascular damage will be characterized. The investigators plan to enroll at least 200 consecutive type 1 diabetes mellitus (T1DM) patients who meet all the inclusion criteria and none of exclusion criteria. conditions: Diabetes Mellitus, Type 1 conditions: Cardiovascular Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective collection of data with diagnostic procedures different from standard clinical care in a specific cohort of patients. primaryPurpose: PREVENTION masking: NONE count: 200 type: ESTIMATED name: Standard of care plus additional examinations measure: Stratify cohort of type 1 diabetes patient according to ESC/EASD 2019 guidelines. measure: Stratify cohort of type 1 diabetes patient according to the Steno Type 1 Risk Engine (ST1RE). measure: Prevalence of cardiovascular disease in type 1 diabetes patients measure: Prevalence of diabetic retinopathy measure: Prevalence of diabetic nephropathy measure: Prevalence of diabetic neuropathy measure: CT-derived calcium score measure: Carotid intima-media thickness measure: Prevalence of endothelial dysfuntion (evaluated using peripheral arterial tone detection method) measure: Stratify type 1 patient cohort by Food Frequency Questionnaire (FFQ) measure: Stratify type 1 patient cohort by the Mediterranean Diet Adherence Screener score (MEDAS) measure: Stratify type 1 patient cohort by psychological profiles using psychological validated questionnaires. measure: Stratify type 1 patient cohort by lipid profile measure: Stratify type 1 patient by glucose control using HbA1c and Ambulatory Glucose Profile metrics. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Centro Cardiologico Monzino status: RECRUITING city: Milan zip: 20138 country: Italy name: Stefano Genovese, MD role: CONTACT phone: 0258002327 email: stefano.genovese@cardiologicomonzino.it lat: 45.46427 lon: 9.18951 facility: Policlinico di Monza status: NOT_YET_RECRUITING city: Monza zip: 20900 country: Italy name: Gianluca Perseghin, MD role: CONTACT phone: +390392810430 email: gianluca.perseghin@policlinicodimonza.it lat: 45.58005 lon: 9.27246 hasResults: False